Lupin is trading higher by 1.3% at Rs 865 on NSE after the pharmaceutical company said that it has received approval from the United States Food and Drug Administration (US FDA) to market a generic version of Warner Chilcott Company LLC's 'Ovcon 35' tablets, an oral contraceptive, in the American market.
The company has received final approval for its VyfemlaTM Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg) from the US FDA. Lupin's US subsidiary Lupin Pharmaceuticals Inc. shall commence marketing the product shortly, the company said in a regulatory filing.
According to IMS MAT March sales data, Warner Chilcott Company's Ovcon 35 tablets had annual US sales worth around $22.3 million.
The stock opened at Rs 855 and has seen a combined nearly 90,000 shares changing hands on the counter till 0945 hours on NSE and BSE.
The company has received final approval for its VyfemlaTM Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg) from the US FDA. Lupin's US subsidiary Lupin Pharmaceuticals Inc. shall commence marketing the product shortly, the company said in a regulatory filing.
According to IMS MAT March sales data, Warner Chilcott Company's Ovcon 35 tablets had annual US sales worth around $22.3 million.
The stock opened at Rs 855 and has seen a combined nearly 90,000 shares changing hands on the counter till 0945 hours on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%